Expression of microRNA-379 reduces metastatic spread of prostate cancer.

Autor:	Cassidy JR; Department of Laboratory Medicine, Division of Translational Cancer Research, Lund University, Lund, Sweden., Voss G; Department of Laboratory Medicine, Division of Translational Cancer Research, Lund University, Lund, Sweden., Underbjerg KR; Department of Laboratory Medicine, Division of Translational Cancer Research, Lund University, Lund, Sweden., Persson M; Department of Laboratory Medicine, Division of Translational Cancer Research, Lund University, Lund, Sweden., Ceder Y; Department of Laboratory Medicine, Division of Translational Cancer Research, Lund University, Lund, Sweden.
Jazyk:	angličtina
Zdroj:	Frontiers in oncology [Front Oncol] 2023 Sep 12; Vol. 13, pp. 1252915. Date of Electronic Publication: 2023 Sep 12 (Print Publication: 2023).
DOI:	10.3389/fonc.2023.1252915
Abstrakt:	Introduction: Prostate cancer (PCa) is the most common type of cancer in males, and the metastatic form is a leading cause of death worldwide. There are currently no curative treatments for this subset of patients. To decrease the mortality of this disease, greater focus must be placed on developing therapeutics to reduce metastatic spread. We focus on dissemination to the bone since this is both the most common site of metastatic spread and associated with extreme pain and discomfort for patients. Our strategy is to exploit microRNAs (miRNAs) to disrupt the spread of primary PCa to the bone. Methods: PCa cell lines were transduced to overexpress microRNA-379 (miR-379). These transduced PCa cells were assessed using cell growth, migration, colony formation and adhesion assays. We also performed in vivo intracardiac injections to look at metastatic spread in NSG mice. A cytokine array was also performed to identify targets of miR-379 that may drive metastatic spread. Results: PCa cells with increased levels of miR-379 showed a significant decrease in proliferation, migration, colony formation, and adhesion to bone cells in vitro . In vivo miR-379 overexpression in PC3 cells significantly decreased metastatic spread to bone and reduced levels of miR-379 were seen in patients with metastases. We identified GDF-15 to be secreted from osteoblasts when grown in conditioned media from PCa cells with reduced miR-379 levels. Discussion: Taken together, our in vitro and in vivo functional assays support a role for miR-379 as a tumour suppressor. A potential mechanism is unravelled whereby miR-379 deregulation in PCa cells affects the secretion of GDF-15 from osteoblasts which in turn facilitates the metastatic establishment in bone. Our findings support the potential role of miR-379 as a therapeutic solution for prostate cancer. Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. (Copyright © 2023 Cassidy, Voss, Underbjerg, Persson and Ceder.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu